My Post-FDA Over-The-Weekend Watchlist:
All of these biotechs have phase one cancer treatment clinical-trial data releases this weekend. Based on my research, these are the ones that I think are most likely to release good data. Since they are all in phase one, it is likely that we see a gap up on Monday and a solid downtrend from...
My biotech watchlist for this week:
Like and follow for weekly bio watchlists :) Also please comment your favorite tickers; I would love to hear what you guys think.
Unity Biotechnology is a pharmaceutical company focused on creating a drug that will extend the years people can live unburdened by disease. This drug has shown a great deal of promise and is currently in phase two clinical trials. As the trials progress, we can expect the price to rise dramatically, and given the current uptrend, My forecast is $18.90 by May...
Jounce Therapeutics Inc. is a clinical-stage immunotherapy company that focuses on developing cancer treatments that aide the patient's immune system in attacking the tumors. This is completely revolutionizing the way we treat cancer, and this company has plenty of room to grow. Target $17 within the next year or so. However, that is only in the next year. Jounce...
Surface Oncology is a strong company with lots of big pharma ties. Had a brief run-up recently but was rejected by that .786 fib resistance level. Looking to break that level and see major growth this year. Target $22.88 for 182.65%. Like and follow for more biotech ideas :) Happy Trading!